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Current status of vascularized composite tissue 
allotransplantation
Vascularized composite tissue allotrans-
plantation (VCA) - recent developments 
leading to a clinical reality
Organ and tissue transplants including the replacement of  
limbs have been a long-standing dream.[1] At the same time, 
rapid advances in solid organ transplantation (SOT) paved 
the way for the current success of  VCAs.
World War II initiated a more in-depth exploration of  skin 
transplants for the treatment of  burned warriors. These 
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efforts had subsequently inspired a team in Boston led 
by Joseph E. Murray to perform the first successful SOT 
between identical twins.[2] The same team went on in the 
following years to establish successful renal transplants 
between nonidentical living donors, followed shortly 
thereafter by the first renal transplant from a deceased donor 
with chemical immunosuppression.[3,4]
The first successful human VCA, an en block digital flexor 
tendon, was conducted by Erle E. Peacock Jr. in North 
Carolina in the absence of  immunosuppression in 1957 
and coined the term composite tissue allotransplantation 
(CTA).[5] A first hand transplant, although clinically 
not successful, was performed in 1964 with chemical 
immunosuppression in Ecuador by Robert Gilbert.[6] A long 
period of  stagnation in VCA followed, mainly based on 
the paradigm that the potent antigenicity of  the skin could 
not be sufficiently managed by immunosuppressants.[7] In 
the meantime, immunosuppression became more refined 
for SOT.[8,9] Addressing the paradigm of  intensified 
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Vascularized composite tissue allotransplantation (VCA) offers treatment options of complex functional deficiencies that cannot 
be repaired with conventional reconstructive methods. VCAs consist of blocks of functional units comprising different tissue 
types such as skin, bone, muscle, nerves, blood vessels, tendons, ligaments and others, and are thus substantially different from 
the composition of organ transplants. The field of VCA has made fascinating progresses in the recent past. Among other VCAs, 
numerous successful hand, face and limb transplants have been performed in the world. At the same time, specific questions 
in regard to innate and adaptive immunity, consequences of ischemia/reperfusion injury, immunosuppression, preservation, and 
regenerative capacity remain. In spite of this, the field is poised to make significant advances in the near future.
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antigenicity in VCAs, interesting experimental work in 
the early 1990s demonstrated that the transplantation of  a 
whole limb was linked to a less intense immune response 
as compared to individual components such as the skin.[10]
First successful limb transplantations in pigs, treated with a 
triple immunosuppressive therapy consisting of  cyclosporin 
(CsA), mycophenolate mofetil (MMF), and prednisone 
encouraged a team led by Jean-Michel Dubernard in 
France to conduct the first successful hand transplantation 
in 1998.[11,12] Additional hand transplants were performed 
rapidly thereafter in the USA and China, while other 
successful composite tissue transplants such as larynx and 
knee transplants were subsequently reported.[13,14] First 
successful face transplants were performed in 2005 in France 
and thereafter in China and the US (Cleveland and Boston). 
In 2013, the transplantation of  bilateral transfemoral lower 
extremities was reported[15] [Figure 1]. Most recently, an 
important regulatory issue has been resolved and VCAs 
are now officially covered by United Network for Organ 
Sharing (UNOS) guidelines since 2013 in the USA, which 
ended a long-lasting discussion whether allocation of  VCAs 
should fall under the regulatory framework of  tissue or 
organ transplants.[28]
Although major unsolved issues including the need for a 
more refined immunosuppression and missing long-term 
results remain, the last decade has seen major advances in 
VCA [Table 1].
Immunosuppression and immune modulation in VCA
The immunosuppressive regimen in VCA continues to 
evolve in parallel with SOT. Indeed, the refinement of  long-
term immunosuppression seems of  particular importance 
for the ‘life-giving’ rather than ‘life-saving’ VCA approach. 
At the same time, VCAs offer opportunities for immuno-
modulation such as the transplantation of  bony structures 
(including bone marrow (BM)) with potential relevance of  
tolerance enabling protocols and the application of  topical 
treatment.
Face transplantation
In face transplantation, most patients received an 
induction treatment with anti-thymocyte globulin (e.g., 
thymoglobulin) in varying doses of  1-2 mg/kg/day[16,29] for 
up to 10 days[29,30] after transplantation. Some teams decided 
on an induction treatment with an anti-interleukin-2 
receptor (anti-IL-2R) antibody (e.g., basiliximab).[31,32] 
Steroids were administered in 500-1,000 mg intravenous 
(i.v.) boluses of  methylprednisolone,[33,34] or, alternatively 
250-500 mg prednisone[17,35] on the day of  transplantation, 
then tapered to daily prednisone doses of  5-20 mg/day. 
In the VCA program at Brigham and Women’s Hospital 
in Boston, we were able to wean all our nonsensitized 
recipients off  steroids.[31,36]
Maintenance therapy is usually initiated on day 1 with 
calcineurin inhibitors (CNIs), in general tacrolimus, in 
all reported face transplantations with doses adjusted to 
maintain through levels of  10-15 ng/ml during the first 
1-3 months in majority of  cases and subsequent tapering 
to levels as low as 3-5 ng/ml.[16,30,37] Moreover, MMF was 
part of  the standard triple immunosuppression regimen 
in face transplantation and was uniformly prescribed at 
dosages of  2 g/day early after transplantation and tapered 
thereafter.[17,33] Some teams have tested the feasibility of  
CNI free protocols. A progressive decline in renal function 
Figure 1: Progress in clinical vascularized composite tissue allotransplantation (VCA): Year of transplantation or publication.[12,13,15-27]
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or malignancies have prompted some to switch to CNI 
free maintenance immunosuppression based on sirolimus 
treatment with a targeted trough level of  8-12 ng/ml.[37,38]
Early acute rejections (grade I and II) have usually 
been treated with increasing dosages of  maintenance 
immunosuppression, in some cases, topical treatment 
with tacrolimus and clobetazol ointments, and prednisone 
mouthwashes.[17,31,35] In the absence of  adequate response 
or in more advanced rejections (grade III), steroid pulses 
have been necessary. A few cases required an escalation to 
anti-thymocyte globulin therapy plus a modification in the 
maintenance immunosuppression protocol.[6]
Of  note, not all low grade acute rejections have required 
treatment and most centers have been assessing both 
histology and clinical presentation.[34] It remains unclear 
at this point, if  low grade rejections are self-limiting or 
if  the currently applied pathological scores necessarily 
distinguish rejection from unspecific-inflammatory events. 
Extracorporeal photochemotherapy (ECPCT) has been 
introduced in a few patients. This immunomodulatory 
approach demonstrated a complementary effect on 
preventing rejections in the absence of  the known side 
effects of  conventional immunosuppression. Although the 
mode of  action of  ECPCT is not completely clear, ECPCT 
has been used successfully both long-term in patients 
with ongoing low grade rejections and in patients with 
simultaneous rejections and infections.[35,39]
Hand transplantation
Immunosuppression in hand transplantation parallels 
largely to regimens in other VCA approaches including face 
transplantation. At the same time, the experience is larger 
and ‘stakes’ may be slightly lower, thus allowing pushing 
the envelope in this area. Most teams around the world 
have utilized a triple immunosuppression with tacrolimus, 
MMF and methylprednisolone, and an induction treatment 
with either a polyclonal antithymocyte globulin or a 
monoclonal anti-IL-2R.[12] More recently, alemtuzumab 
(an anti-CD52 antibody) has been utilized by some centers 
as an induction agent.[40] Along the same line as with the 
experience in face transplantation, CNI-based protocols 
have been switched to sirolimus subsequently due to 
side-effects such as unstable glucose blood levels.[41,42]
Clinical and pathological diagnosis of acute rejection in VCA
VCAs typically consist of  various tissues originating from 
different embryological germ layers.[43] It is assumed that 
the skin is most sensitive to rejection, while vessels, muscles, 
and especially nerves are afflicted to a lesser degree.[44] Local 
or scattered erythema is usually considered as a clinical 
sign of  an early acute rejection. Moderate acute rejections 
present with pink erythematous macules, more advanced 
acute rejections with scaly papules or plaques, and the 
irreversible grade IV state with necrosis and/or ulceration 
of  the graft.[44]
Scoring systems based on histopathological findings 
classifying acute rejections of  VCAs have been proposed 
by several groups.[45-48] In 2007, an international team of  
surgeons, pathologists, and basic scientists with experi-
ences in VCA met in Banff  and agreed on a standardized 
classification. Scores are mainly based on localization and 
intensity of  infiltrates in the skin. Future additions to the 
current Banff  score have been proposed and may include 
a graded assessment of  clinical symptoms, supplemental 
immunohistological evaluations characterizing infiltrat-
ing cells (e.g., CD4+, CD8+ T cell or B cell) and humoral 
rejections.[43]
According to the Banff-07 classification, acute cellular 
mediated rejection is graded into 5 categories. Absent 
or rare infiltration define grade 0; grade I rejection is 
characterized by the appearance of  mild perivascular 
infiltration. Advanced infiltrates with or without mild 
involvement of  the epidermis, and/or adnexa defines 
grade II; while the addition of  epithelial apoptosis, dys-
keratosis, and/or keratinolysis defines grade III. Grade 
IV, finally, includes frank necrosis of  epidermis, or other 
skin structures.[43]
It has been suggested that the current Banff-07 classifi-
cation for VCA may not be reflective of  critical aspects 
of  rejection. In a series of  more than 100 biopsies of  
face transplant recipients, rejections have been linked to 
lymphocyte associated injuries in epidermal rete ridges, 
follicular infundibula and dermal microvessels. Of  note, 
Table 1: Current success and challenges in VCA
Achievements Challenges
Excellent esthetic and functional 
outcome
Minimization of immunosuppression, 
tolerance induction
Multidisciplinary approach Protocols for sensitized patients
Recognition as organ, regulated 
by OPTN
Improved monitoring
Excellent patient and graft survival Mechanisms of rejection
Acute cellular and humoral rejection 
Chronic graft deterioration
Nerve regeneration
Definition of acceptable ischemic times
Refined organ preservation
VCA = Vascularized composite tissue allotransplantation, OPTN = Organ Procurement 
and Transplantation Network
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during active rejection, infiltrates consisted predominantly 
of  lymphocytes of  donor origin with an immunophenotype 
typical of  resident memory T-cell subsets. These results may 
not only provide additional information for a more concise 
grading system, but may also provide novel biological in-
sights into the mechanisms of  VCAs.[49]
Antibody-mediated rejection (AMR)
A complex medical history including trauma and blood trans-
fusions with subsequent sensitization is probable in patients 
qualifying for VCAs. In renal transplantation, patients have 
been transplanted against positive complement-dependent 
cytotoxicity (CDC) cross-matches with extensive pre- and 
post-transplant immunosuppression.[50] Whether similar 
approaches may also apply in VCA is largely unknown. 
VCAs have usually been followed closely for donor-recipient 
crossmatches comparable to the approach in SOT. Thus 
far, there have been only very few reports of  either AMR 
in VCA,[51,52] circulating donor-specific antibodies (DSAs), 
or the deposition of  the complement product C4d in VCA 
recipients. [52,53] Of note, AMR is currently not part of  the 
Banff-07 VCA classification system.
Pretransplant panel reactive antibody (PRA) scores are usu-
ally used to test the degree of  sensitization in solid organ and 
VCA recipients alike. The score provides a relative estimate 
with a 100% PRA predicting a positive crossmatch against 
any given donor. We have recently successfully treated a 
highly-sensitized patient who developed a fulminant AMR. 
This patient was treated with an intensified immunosuppres-
sion consisting of  plasmapheresis, eculizumab, bortezomib 
and campath-1H.[54]
DSAs occurring late after hand transplantation have been 
reported recently. Rituximab (i.e., anti-CD20 antibody) 
normalized not only clinical symptoms, but also histologi-
cal findings and DSA levels.[55] Another hand transplanta-
tion patient presented with an aggressive thickening of  
arterial walls, detected by ultrasound biomicroscopy, an 
advanced imaging technique capable of  revealing arterial 
thickening noninvasively. Further tests correlated findings 
with the deposition of  the complement product C4d. Plas-
mapheresis, i.v. immunoglobulin, and a switch from MMF 
to sirolimus inhibited further progression of  the lesions.[56]
Clearly, humoral immune responses are expected to gain 
further interest and relevance in VCA.
Chronic graft deterioration in VCA
Although the skin is under constant surveillance, different 
properties of  VCAs including muscle, bone, vessels, nerves, 
and other tissues may undergo immunologic and degenera-
tive processes in the absence of  direct visibility. The concept 
of  ‘split rejection’, a process in which specific tissues un-
dergo deterioration or immune attacks at a different tempo 
or intensity may also be of  relevance impacting chronic 
graft deterioration in VCA.[57] As in SOT, mechanisms 
of  chronic graft deterioration are also not well-defined in 
VCA. Histological and clinical findings including vascular 
narrowing, loss of  adnexa, skin and muscle atrophy, fibrosis 
of  deep tissue, myointimal proliferation, and nail changes 
indicate chronic rejection in VCA.[43]
Although confirmed, acute rejection episodes are frequent 
in VCA, and the field is looking back to a reasonable 
clinical experience, reports of  chronic graft deterioration 
in VCA remain rare. At the same time, clinical evidence 
of  chronic rejection exists: For example, a hand transplant 
recipient presented with arterial narrowing while superfi-
cial biopsies remained normal. DSAs were absent at the 
same time. Vasculopathy progressed, requiring subsequent 
amputation due to ischemia. Histological examination 
demonstrated predominantly vascular pathologies with 
hyperplasia of  the intima in all donor arteries and involve-
ment of  the venous tissue as well. Of  note, skin biopsies 
were scored grade 0-I.[56] Other patients with clinical 
symptoms resembling chronic changes including atrophic 
skin and thinning of  nails, pain, cold intolerance and 
compromised functionality have been reported. Clinical 
symptoms correlated with arterial narrowing and occlusion 
in addition to loss of  adnexa, epidermal hyperkeratosis and 
perivascular inflammation.[58]
Mechanisms of  chronic graft deterioration remain obscure 
both in VCA and SOT. Hind-limb allografts in rats developed 
chronic changes following multiple acute rejection episodes, 
which were treated suboptimally. Myointimal proliferation, 
causing subtotal arterial occlusion was observed by day 90, 
while muscular atrophy and fibrosis became evident by 
day 60. While fibrosis has thus far been mainly linked to 
ischemia subsequent to advanced vasculopathy, profibrotic 
gene expression implicated additional causes, such as 
infiltrating macrophages and direct injury to muscle cells 
as aspects of  chronic changes. Other interesting aspects 
include findings of  mild vasculitis; while skin, muscle, and 
bone were unaffected, providing further evidence of  the 
relevance of  split rejection in VCA.[59]
Clinical and experimental tolerance approaches in VCA
Tolerance protocols have been attempted in both experi-
mental and clinical settings. The first human face trans-
plant recipient received 2 injections of  donor BM cells in 
consistency with the Miami protocol, however, long-term 
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microchimerism could not be documented and triple immu-
nosuppressive therapy plus additional immunomodulatory 
treatment were necessary to control rejection episodes.[37]
The Pittsburgh protocol, applied in 5 hand transplantation 
patients, was able to keep patients on a maintenance tacro-
limus monotherapy, although controls have been missing. 
This protocol consists of  a lymphocyte-depleting induction 
therapy with alemtuzumab in combination with methyl-
prednisone and a single, unmodified, donor BM cell infu-
sion on day 14 after transplantation. DSA and C4d deposits 
detected in parallel to acute T cell rejections responded to 
topical treatment or methylprednisone infusions. Deep bi-
opsies by 1 and 2 years revealed only focal muscle atrophy. 
Evaluations by high-resolution ultrasound biomicroscopy 
demonstrated minor to moderate vascular irregularities 
in 2 cases with some narrowing of  luminal diameter and 
increased intimal-media thickness, respectively.[40] Of  note, 
peripheral chimerism was not detected in any of  the VCA 
patients receiving the Pittsburgh protocol.
Stable mixed chimerism, in contrast, was achieved in 
VCA transplants across major histocompatibility complex 
(MHC) barriers in large animal models. In a pig model, 
a non-myeloablative conditioning regimen with T cell 
depletion by CD3-immunotoxin, total body irradiation, and 
donor-specific hematopoietic stem cell transfusion (HCT) 
was followed by a 45 day course of  CsA. VCA transplants 
consisting of  a vascularized full thickness skin flap were 
performed at varying intervals after HCT. Rejections were 
absent during an observation period up to 500 days. Of note, 
2 animals with very high chimerism levels developed graft 
versus host disease (GvHD). Nevertheless, GvHD could be 
contained with an immunosuppression consisting of  CsA 
and steroids.[60] Achieving tolerance or the minimization of  
immunosuppression will be critical in improving the clinical 
applicability of  VCAs, and future research will certainly 
focus on this area.
Ischemia/reperfusion injury (IRI)
Both ischemia and reperfusion set mechanisms in place that 
initiate innate and adaptive immune responses contributing 
to acute rejection and chronic graft deterioration.[61,62]
In the presence of  inadequate blood supply and oxygen 
deprivation, imbalances of  cellular ion homeostasis and 
an augmented permeability of  cell membranes occur 
simultaneously.[63] Anaerobic metabolism and a buildup 
of  lactate results in accumulation of  proinflammatory 
mediators.[64] Of  note, restored blood flow does not restore 
function immediately, but leads to additional damages 
recognized as reperfusion injury. During IRI endothelial, 
parenchymal and immune cells become activated and 
reactive oxygen species, inflammatory cytokines, and 
complement products contribute to a furthermore 
augmented injury. Additional consequences include 
an impaired microvascular perfusion with secondary 
ischemia in the transplanted organ and the promotion of  
a ‘cytokine storm’ that may finally lead to the development 
of  systemic inflammatory response syndrome (SIRS).
[63,65] Consequences of  IRI have been extensively analyzed 
in SOT. IRI has only recently received attention in VCA 
where injury patterns of  skeletal and cardial muscle 
demonstrated parallels.[64] As VCA is composed of  
different tissues, consequences of  IRI may differ in a 
tissue-specific manner. Muscle and adipose tissue have an 
enhanced metabolism and are therefore more susceptible 
to damage.[66] Of  note, viable skin could still be found in 
musculocutaneous autografts, although muscular tissue 
had already demonstrated necrotic changes.[67,68]
Time of  tolerable ischemia, although of  utmost clinical 
relevance, has thus far not been defined. In rat experiments, 
ischemic times exceeding 12 h drastically reduced the 
survival of  musculocutaneous flaps. A histological analysis 
of  biopsies in flaps with brief  or prolonged ischemia 
(24 h) revealed no difference in the early onset of  acute 
rejections, but demonstrated an accelerated inflammation 
in grafts with a prolonged ischemia.[69] Other experiments 
have also shown that prolonged ischemia in models 
of  VCA-augmented adaptive immunity and increased 
rates of  acute rejections.[70] Tolerable clinical ischemic 
times are currently not defined and clinical practice has 
aimed for brief  periods of  ischemia.[16,29,34,71,72] Exploring 
mechanisms of  IRI in VCA will be critical as tolerable 
prolonged ischemia will increase the availability of  donors. 
To this end, novel preservation, developed in SOT are 
noteworthy.[73] Pulsatile perfusion has been successfully 
used clinically in SOT and linked to endothelial and 
epithelial protection.[74-76] Future studies in VCA will need 
to explore if  similar concepts and mechanisms may also 
be of  relevance and benefit in VCAs.
Conclusions
VCA has become a clinical reality during the last decade. 
Face and hand transplants have been successfully performed 
with excellent functional and esthetic outcomes by several 
centers in the world, and some patients have achieved a 
minimization of  immunosuppression. While progress 
has been enormous, several open questions in regard to 
mechanisms of  rejections, tolerance or minimization of  
immunosuppression, and the effects of  unspecific injuries, 
consequences of  IRI remain. Although critical aspects of  
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the success of  VCA are based on the experience in SOT, 
VCA-specific aspects need to be recognized and addressed. 
Most importantly, VCA is as much as SOT, a field which 
will thrive in a multidisciplinary approach synergizing the 
clinical and research expertise in tackling many unresolved 
issues in the field.
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